Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis.
about
DICOM for quantitative imaging biomarker development: a standards based approach to sharing clinical data and structured PET/CT analysis results in head and neck cancer researchPositron Emission Tomography for the Response Evaluation following Treatment with Chemotherapy in Patients Affected by Colorectal Liver Metastases: A Selected ReviewPrognostic significance of volume-based PET parameters in cancer patients.State-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PET18F-FDG PET/CT role in staging of gastric carcinomas: comparison with conventional contrast enhancement computed tomography.The value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration.Influence of rigid coregistration of PET and CT data on metabolic volumetry: a user's perspectiveCharacterization of PET/CT images using texture analysis: the past, the present… any future?Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT.PET/CT Assessment of Response to Therapy: Tumor Change Measurement, Truth Data, and Error.[18F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis.PET/CT in Oncology: Current Status and Perspectives.Differential Diagnosis of Borderline Ovarian Tumors from Stage I Malignant Ovarian Tumors using FDG PET/CT.Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer.Correlation of intra-tumor 18F-FDG uptake heterogeneity indices with perfusion CT derived parameters in colorectal cancer.Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET.Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas.Association between Volumetric Analysis of Lung Metastases on F-18-fluoro-2-deoxy-D-glucose Positron Emission Tomography/Computed Tomography and Short-term Progression after I-131 Therapy for Differentiated Thyroid Carcinoma.Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer.18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic ResponseMethodological considerations in quantification of oncological FDG PET studies.Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.Instrumentation factors affecting variance and bias of quantifying tracer uptake with PET/CT.Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographicsPositron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapyPositron Emission Tomography (PET) in OncologyImaging and cancer: a review.From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.Volumetric PET/CT parameters predict local response of head and neck squamous cell carcinoma to chemoradiotherapyPrognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy.Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studiesThe Role of (18)F-FDG PET/CT as a Prognostic Factor in Patients with Synovial SarcomaPrognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.Prognosis Related to Metastatic Burden Measured by ¹⁸F-Fluorocholine PET/CT in Castration-Resistant Prostate Cancer.Prognostic value and clinical correlations of 18-fluorodeoxyglucose metabolism quantifiers in gastric cancerProspective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases.The future of hybrid imaging-part 2: PET/CT.Respiration-Averaged CT for Attenuation Correction of PET Images - Impact on PET Texture Features in Non-Small Cell Lung Cancer PatientsMetabolic Tumour Burden Measured by 18F-FDG PET/CT Predicts Malignant Transformation in Patients with Neurofibromatosis Type-1.Impact of point spread function modelling and time of flight on FDG uptake measurements in lung lesions using alternative filtering strategies
P2860
Q24658635-C3305006-68E7-4130-A872-A4DBEC3D1B99Q27009240-AF37FE9A-71AE-4478-B751-466450EFC949Q27687836-10EA700E-1F65-4663-941B-ADA01108551BQ27694674-99407EC8-4C53-45EC-A135-78074FB9C0BFQ30400422-C3269510-46CD-4159-9995-409FAB9EAFE9Q30584396-8DECFA3C-B0E1-4A93-B31B-DD18646CE6A2Q30724225-8DAF196F-8F91-47A7-BBDD-95CC04CB8335Q30837034-EB0F81A5-18ED-424D-8BF4-D71B4C39587CQ33413585-59D70E1A-5987-4E0F-B773-A59DD88B0D0DQ33517102-9C6A317C-A997-4511-B4F7-9BAAE83213D6Q33612767-F8172BDE-1992-413E-A096-6CBC89505F6EQ33665109-074D26C5-8620-423E-893C-D4AE08F7CC48Q33700938-A81418D5-5F75-43DE-A781-ED157EE84D2FQ33750115-B8131601-BDCE-4237-88FC-BDDE5E423549Q33753620-4E2457F6-AB80-416D-80EC-57C510809820Q33793870-2209F0EB-BEDA-4F83-902F-41D15ABEF08CQ33797380-13FF129F-E6B5-47C4-8504-5D4DD3491CFFQ33827725-18A2781C-F23F-4627-B242-31043C5B9483Q33896012-B95202A2-6CBB-4C8C-A542-ACC961E54D1CQ33904549-041ED133-8D9B-4DE7-8E9C-A18E29EA2A76Q33915164-D3F56ED6-18DA-4556-814B-33FC599E7D8CQ34023973-16316F4E-481A-4DBB-9436-ADA68507C4D3Q34336023-0286C9C9-555F-4C22-A5EC-A301A07C5E3DQ34382399-14FF1BB0-BB31-4BDA-A16E-8E2EB6FDD9BEQ34517660-610602BC-578D-403B-943B-3825C02D9FECQ34774840-CA128109-E217-4AD5-9100-4C60FC72D964Q34977050-B6696EBA-7FA4-49D8-88A5-F50156E6B65FQ34978457-65F97278-F192-4CAE-BF02-9C136ABD9118Q34998582-22CE38C9-D3AE-48A4-AF98-1F2EBFFB1F6FQ35129698-778BBC55-6096-4E9F-882E-72E48C098B9BQ35151263-DCE1F175-B04E-4B73-AFB1-D4D84D60F22AQ35162720-C1391B03-11D5-4B54-B577-650825C304CEQ35439403-B1C238C7-C5D3-4194-9DD7-2F0BD633175BQ35582133-6D45DFA8-DC95-48B9-845F-D5C0923E2D46Q35625394-96F12502-26F4-44A7-9F2A-8496C631C134Q35761121-1D902AD0-438E-4F98-94C1-CDD22684D9A4Q35786046-E001F015-42B3-441C-82D2-FB8CEAE7337CQ35940876-515AEF2B-F9AA-45D4-8588-9956A329424EQ35961361-4DEE5663-4725-42C9-B61A-3BB02D4C8687Q35983497-86F9F56C-A40C-416E-A4BC-87A9B67ECBD6
P2860
Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Tumor Treatment Response Based ...... ge in Total Lesion Glycolysis.
@en
Tumor Treatment Response Based ...... ge in Total Lesion Glycolysis.
@nl
type
label
Tumor Treatment Response Based ...... ge in Total Lesion Glycolysis.
@en
Tumor Treatment Response Based ...... ge in Total Lesion Glycolysis.
@nl
prefLabel
Tumor Treatment Response Based ...... ge in Total Lesion Glycolysis.
@en
Tumor Treatment Response Based ...... ge in Total Lesion Glycolysis.
@nl
P2093
P1476
Tumor Treatment Response Based ...... nge in Total Lesion Glycolysis
@en
P2093
Alfred E. Cohen
Cecille Casilla
Henry W.D. Yeung
Homer A. Macapinlac
John L. Humm
Jose Guillem
Madhu Mazumdar
Martin Karpeh
Neil Srivastava
Robert Downey
P304
P356
10.1016/S1095-0397(99)00016-3
P577
1999-05-01T00:00:00Z